OBS - Office Based Surgery Now Offered at Ginsberg Eye

Two New Scientific Articles Showing the Success of PRP Autologous Serum Eyedrops for Treatment of Dry Eyes

Symptomatic Dry Eye Treatment with Autologous Platelet-Rich Plasma

Jorge L Alio 1, José R Colecha, Silvia Pastor, Alejandra Rodriguez, Alberto Artola
Clinical Trial Ophthalmic Res
2007;39(3):124-9. doi: 10.1159/000100933. Epub 2007 Mar 19.
PMID: 17374962 DOI: 10.1159/000100933

Abstract

Background: Autologous platelet-rich plasma (PRP) has been proven to be very effective on tissue regeneration and wound healing. Here we investigate the potential use of PRP in the treatment of symptomatic dry eye.

Methods: Eighteen consecutive patients with symptomatic dry eye were treated with topical PRP and followed up for 1 month. Disappearance of subjective symptoms, increase in best corrected visual acuity, tear meniscus, tear breakup time, decrease in inflammation, fluorescein staining and improvement in impression cytology were measured.

Results: Symptoms improved significantly in 89% of the patients, 28% improved at least 1 line of best corrected visual acuity. A significant improvement on lachrymal meniscus and conjunctival hyperemia and a decrease or disappearance of corneal fluorescein staining were observed. Impression cytology revealed a significant increase in conjunctival goblet cells.

Conclusion: Treatment of patients suffering from significant dry eye symptoms with autologous RPR proved to be very effective, improving both patient symptoms and major clinical signs.

Treatment of Dry Eye Disease with Autologous Platelet-Rich Plasma: A Prospective, Interventional, Non-Randomized Study

Jorge L Alio 1 2, Alejandra E Rodriguez 3, Renan Ferreira-Oliveira 4 3, Dominika Wróbel-Dudzińska 4 3, Ahmed A Abdelghany 4 5 6
Ophthalmol Ther
2017 Dec;6(2):285-293. doi: 10.1007/s40123-017-0100-z. Epub 2017 Aug 8.
PMID: 28791607 PMCID: PMC5693817 DOI: 10.1007/s40123-017-0100-z

Abstract

Introduction: The objective of this study was to evaluate the use of autologous platelet-rich plasma (PRP) eye drops as monotherapy for the treatment of moderate to severe cases of dry eye disease.

Methods: Three hundred and sixty-eight patients with moderate to severe dry eye disease (DED) were included in this prospective case series. Subjects were classified as evaporative DED (EDED) or aqueous deficient DED (ADDED). Improvement of the DED subjective symptoms, corneal fluorescein staining (CFS), and corrected distance visual acuity (BCVA) were evaluated. We also analysed how many rounds of PRP therapy were used.

Results: Two hundred and ninety-seven (80.7%) patients were women, and 71 (19.3%) were men. Two hundred and thirty-two (63%) patients had EDED, while 136 (37%) had ADDED. After 6 weeks of monotherapy treatment with autologous PRP, dry eye symptoms improved in 322 (87.5%) cases. A decrease of CFS was observed in 280 (76.1%) patients. One hundred and six (28.8%) patients improved at least 1 line of BCVA. The scores in the ocular Surface Disease Index and the Oxford scale of corneal fluorescein staining decreased statistically after the treatment (p < 0.05).

Conclusion: The topical use of autologous platelet-rich plasma as monotherapy is an effective treatment to improve signs and symptoms in patients suffering from moderate to severe chronic DED.